Cargando…
The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings
BACKGROUND: The PROMOTE study aims to measure long-term antiretroviral treatment (ART) safety and adherence; compare HIV disease progression; assess subsequent adverse pregnancy outcomes; evaluate effect of ART exposure on growth and development in HIV-exposed uninfected children; and assess long-te...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292608/ https://www.ncbi.nlm.nih.gov/pubmed/30543692 http://dx.doi.org/10.1371/journal.pone.0208805 |
_version_ | 1783380417343127552 |
---|---|
author | Taha, Taha E. Yende-Zuma, Nonhlanhla Aizire, Jim Chipato, Tsungai Wambuzi Ogwang, Lillian Makanani, Bonus Chinula, Lameck Nyati, Mandisa M. Hanley, Sherika Brummel, Sean S. Fowler, Mary Glenn |
author_facet | Taha, Taha E. Yende-Zuma, Nonhlanhla Aizire, Jim Chipato, Tsungai Wambuzi Ogwang, Lillian Makanani, Bonus Chinula, Lameck Nyati, Mandisa M. Hanley, Sherika Brummel, Sean S. Fowler, Mary Glenn |
author_sort | Taha, Taha E. |
collection | PubMed |
description | BACKGROUND: The PROMOTE study aims to measure long-term antiretroviral treatment (ART) safety and adherence; compare HIV disease progression; assess subsequent adverse pregnancy outcomes; evaluate effect of ART exposure on growth and development in HIV-exposed uninfected children; and assess long-term survival of mothers and children. This report primarily describes cohort characteristics at baseline to better understand long-term outcomes. METHODS AND FINDINGS: This is a prospective study. HIV-infected mothers and their children originally recruited in a multisite randomized clinical trial for prevention of perinatal HIV transmission were re-enrolled in PROMOTE. A total of 1987 mothers and 1784 children were enrolled from eight sites in Uganda, Malawi, Zimbabwe and South Africa. Most women (≥75%) reported being married in Malawi and Zimbabwe compared to low proportions in South Africa (4.4% in Durban and 15% in Soweto), and 43.5% in Uganda (p<0.001). There were variabilities in contraceptive practices: injectable contraceptive was the commonest reported method (40.9% overall); implant was the second commonest (15.7% overall); oral contraceptives were common in Zimbabwe; and tubal ligation was common in Malawi and South Africa. At baseline, 97.8% of women reported currently using ART; 96.4% were in WHO clinical class 1 or 2; median CD4 cell count was 825 cells per uL; and viral load was undetectable in 1637 (~85%) of the women. Approximately, 14% of women did not inform their primary partners of their own HIV status, 18% reported that they knew their partners were not HIV tested, and 9% did not know if partner was tested. Overall mean age of children at enrollment was 3.5 years; and 5.7% and 25.0% had weight-for-age and height-for-age z-scores <2 standard deviations, respectively. CONCLUSIONS: These baseline data show high adherence to ART use. However, issues of HIV disclosure and reproductive intentions remain important. In addition to ART and ensuring high adherence, other preventive measures should be included. |
format | Online Article Text |
id | pubmed-6292608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-62926082018-12-28 The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings Taha, Taha E. Yende-Zuma, Nonhlanhla Aizire, Jim Chipato, Tsungai Wambuzi Ogwang, Lillian Makanani, Bonus Chinula, Lameck Nyati, Mandisa M. Hanley, Sherika Brummel, Sean S. Fowler, Mary Glenn PLoS One Research Article BACKGROUND: The PROMOTE study aims to measure long-term antiretroviral treatment (ART) safety and adherence; compare HIV disease progression; assess subsequent adverse pregnancy outcomes; evaluate effect of ART exposure on growth and development in HIV-exposed uninfected children; and assess long-term survival of mothers and children. This report primarily describes cohort characteristics at baseline to better understand long-term outcomes. METHODS AND FINDINGS: This is a prospective study. HIV-infected mothers and their children originally recruited in a multisite randomized clinical trial for prevention of perinatal HIV transmission were re-enrolled in PROMOTE. A total of 1987 mothers and 1784 children were enrolled from eight sites in Uganda, Malawi, Zimbabwe and South Africa. Most women (≥75%) reported being married in Malawi and Zimbabwe compared to low proportions in South Africa (4.4% in Durban and 15% in Soweto), and 43.5% in Uganda (p<0.001). There were variabilities in contraceptive practices: injectable contraceptive was the commonest reported method (40.9% overall); implant was the second commonest (15.7% overall); oral contraceptives were common in Zimbabwe; and tubal ligation was common in Malawi and South Africa. At baseline, 97.8% of women reported currently using ART; 96.4% were in WHO clinical class 1 or 2; median CD4 cell count was 825 cells per uL; and viral load was undetectable in 1637 (~85%) of the women. Approximately, 14% of women did not inform their primary partners of their own HIV status, 18% reported that they knew their partners were not HIV tested, and 9% did not know if partner was tested. Overall mean age of children at enrollment was 3.5 years; and 5.7% and 25.0% had weight-for-age and height-for-age z-scores <2 standard deviations, respectively. CONCLUSIONS: These baseline data show high adherence to ART use. However, issues of HIV disclosure and reproductive intentions remain important. In addition to ART and ensuring high adherence, other preventive measures should be included. Public Library of Science 2018-12-13 /pmc/articles/PMC6292608/ /pubmed/30543692 http://dx.doi.org/10.1371/journal.pone.0208805 Text en © 2018 Taha et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Taha, Taha E. Yende-Zuma, Nonhlanhla Aizire, Jim Chipato, Tsungai Wambuzi Ogwang, Lillian Makanani, Bonus Chinula, Lameck Nyati, Mandisa M. Hanley, Sherika Brummel, Sean S. Fowler, Mary Glenn The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title | The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title_full | The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title_fullStr | The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title_full_unstemmed | The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title_short | The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings |
title_sort | multi-country promote hiv antiretroviral treatment observational cohort in sub-saharan africa: objectives, design, and baseline findings |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292608/ https://www.ncbi.nlm.nih.gov/pubmed/30543692 http://dx.doi.org/10.1371/journal.pone.0208805 |
work_keys_str_mv | AT tahatahae themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT yendezumanonhlanhla themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT aizirejim themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT chipatotsungai themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT wambuziogwanglillian themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT makananibonus themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT chinulalameck themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT nyatimandisam themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT hanleysherika themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT brummelseans themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT fowlermaryglenn themulticountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT tahatahae multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT yendezumanonhlanhla multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT aizirejim multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT chipatotsungai multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT wambuziogwanglillian multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT makananibonus multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT chinulalameck multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT nyatimandisam multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT hanleysherika multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT brummelseans multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings AT fowlermaryglenn multicountrypromotehivantiretroviraltreatmentobservationalcohortinsubsaharanafricaobjectivesdesignandbaselinefindings |